Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Non-Current Deferred Tax Liability came in at $7.0 billion in Q1 2026, up 188.76% year-on-year from $2.4 billion in Q1 2025, and up 3.24% quarter-over-quarter from $6.8 billion in Q4 2025.
Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $7.0 billion for Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $7.0 billion, up 188.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 billion (up 188.76% YoY), and the FY2025 annual result was $6.8 billion, up 177.41% from the prior year.
- Non-Current Deferred Tax Liability came in at $7.0 billion for Q1 2026 at Johnson & Johnson, up from $6.8 billion in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.5 billion in Q1 2022 to a low of $2.4 billion in Q1 2025.
- The 5-year median for Non-Current Deferred Tax Liability is $3.9 billion (2023), against an average of $4.4 billion.
- Across the five-year window, Non-Current Deferred Tax Liability plunged 46.97% in 2023 and soared 188.76% in 2026, its largest moves.
- Johnson & Johnson's Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then sank by 35.44% to $3.2 billion in 2023, then retreated by 23.33% to $2.4 billion in 2024, then surged by 177.41% to $6.8 billion in 2025, then rose by 3.24% to $7.0 billion in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $7.0 billion (Q1 2026), $6.8 billion (Q4 2025), and $6.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 7.01 Bn |
| Mar 29, 2026 | 7.01 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Dec 31, 2023 | 3.19 Bn |